doi: 10.1056/NEJMoa030204
Research has shown that phosphoglycerate dehydrogenase (PHGDH), the enzyme that catalyzes the first reaction in the serine synthesis pathway, was highly upregulated in metastatic breast cancer and was correlated to short patient survival times [135, 136]
Ding et al., 2013
FOR RESEARCH USE ONLY NOT FOR HUMAN OR ANIMAL CONSUMPTION NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE
Hypothetical Dosing Considerations While no evidence-based cagrilintide dosage with retatrutide protocol exists, theoretical frameworks based on monotherapy data suggest several principles that would likely apply: Conservative Approach Principles: Start with minimal doses Perhaps 0.3 mg cagrilintide + 2 mg retatrutide weekly Extended titration periods 16-24 weeks to reach target doses instead of standard 8-12 weeks Alternating escalation Increase one compound while holding the other stable Frequent monitoring Weekly check-ins during initial phases Lower maximum doses Perhaps 1.2 mg cagrilintide + 8 mg retatrutide rather than maximum monotherapy doses These suggestions remain purely speculative and should not be interpreted as clinical recommendations
Han examinado migracin de fibroblastos mediante FAK y paxillina, as como sealizacin asociada con VEGFR2, Akt y eNOS en modelos de angiognesis
